Performance

ALLO -10.17%

Watchlist

Select an item

RETURNS	1D	YTD	1Y	5Y Ann.	Max DD	Sharpe	Div. Yield
ALLO	+1.92%	-22.63%	-10.17%	-44.42%	-66.01%	0.24	0.00%

Summary

ALLO at a glance

ALLO returned -10.17% over the past year and -44.42% a year over five years. Its worst drop in that year was -66.01%, smaller than 8% of stocks on Redstone, and its Sharpe ratio of 0.24 beats 38% of stocks on Redstone. It pays no dividends.

Ranking

How ALLO ranks

Current Drawdown

-65.36%

Rolling Volatility

67.98%

Actions

Metrics

Risk Indicators

Alpha0.89%

Beta1.89x

Sharpe0.24

Sortino0.36

Omega1.04

Calmar-0.15

Martin0.62

Profile

About ALLO

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases.

Sector: Health Care
Industry: Biological Products, (no Diagnostic Substances)
Market cap: $366M
Listed: Oct 2018
Employees: 152
Headquarters: South San Francisco, CA
Website: allogene.com

Comparisons

ALLO: Allogene Therapeutics, Inc.

ALLO at a glance

How ALLO ranks

Current Drawdown

Rolling Volatility

About ALLO

Related comparisons